Press Releases

Press Releases

  • Mar 29, 2021
    NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer

    READ PRESS RELEASE

  • Mar 29, 2021
    NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)

    READ PRESS RELEASE

  • Mar 13, 2021
    NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)

    READ PRESS RELEASE

  • Feb 25, 2021
    NLS Pharmaceutics to Participate in Upcoming Investor Conferences

    READ PRESS RELEASE

  • Feb 2, 2021
    NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering

    READ PRESS RELEASE

  • Jan 28, 2021
    NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering

    READ PRESS RELEASE

  • Jan 21, 2021
    NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy

    READ PRESS RELEASE